ALK-Abelló A/S's Fiscal Year is From January To December - All Figures are in DKK, Millions.
The item "Interest-Expense" stands at 36.69 Million Danish Krones for the trailing twelve months (TTM) period ending 09/30/2025.
ALK-Abelló A/S's third quarter result of 13.43 Million DKK for the item "Interest Expense" represents an increase of 67.84 percent compared to it's second quarter result.
Also, ALK-Abelló A/S's third quarter result of 13.43 Million DKK for the item "Interest Expense" represents an increase of 16.30 percent compared to it's third quarter result of last year.
Looking again at the trailing twelve months series (TTM), ALK-Abelló A/S's third quarter result of 36.69 Million DKK for the item "Interest Expense" represents an increase of 5.41 percent compared to it's second quarter result.
Regarding the One-Year-Change of the series, the current value constitutes a decrease of -14.76 percent compared to the value the year prior.
The 1 year change in percent is -14.76.
The 3 year change in percent is 231.19.
The 5 year change in percent is 74.72.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Interest Expense | 905,699,262,464.00 |
![]() | Johnson & Johnson - Interest Expense | 486,508,953,600.00 |
![]() | AbbVie Inc - Interest Expense | 399,570,305,024.00 |
![]() | Roche Holding AG - Interest Expense | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Interest Expense | 280,205,508,085.11 |